Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (6714)	11/16/2017 10:56:35 AM
From: tuck	Read Replies (2) \| Respond to of 7424

Achillion (ACHN) recovering 20% after yesterday's faceplant of similar magnitude. Pursuant to the end of the J&J HCV collaboration, J&J announced it was shopping its shares. Whoever gets those at $2.75 seems to be getting a deal. However, the lockup on J&J's shares doesn't expire till near year end. This may pull back again, and I think it might be a buy if it does. The company is now a play on its complement factor D program, in P1/2 depending on indication, and said program has achieved proof of concept. Usual caveats of early, small trials apply. I had a modest position before yesterday, and I added on the sell-off such that I'm approximately even at the moment. Cheers, Tuck